

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Ivan N. Rich	Confirmation No.:	5794
Serial No.:	10/059,521	Art Unit:	1641
Filed:	1/29/02	Examiner:	Gailene Gabel
Atty. Docket No.:	6115-007	Customer No.:	29,335
For:	HIGH-THROUGHPUT STEM CELL ASSAY OF HEMATOPOIETIC STEM AND PROGENITOR CELL PROLIFERATION		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF ELECTRONIC FILING**

*I hereby certify that this Supplemental Information Disclosure Statement (along with any paper referred to as being attached or enclosed) is being filed electronically on this the 21<sup>st</sup> day of June, 2007 addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.*

  
\_\_\_\_\_  
Lori Dunham

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**1. Preliminary statements**

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. §1.56.

While this Information Disclosure Statement may contain information "material" to patentability pursuant to 37 C.F.R. §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. §1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

## 2. Identification Of Time Of Filing

This Information Disclosure Statement

*(check and complete (a), (b), (c), (d), or (e))*

(a)  accompanies the new patent application submitted herewith.

(b)  is being filed within three months after the filing date of the application or prior to the mailing date of the first Office action on the merits, whichever is later. 37 C.F.R. §1.97(b)

(c)  is being filed after the time period specified in §1.97(b), but before the mailing date of any final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application (37 C.F.R. §1.97(c)), and is accompanied by:

the statement specified in 37 C.F.R. §1.97(e); or

the fee set forth in 37 C.F.R. §1.17(p);

(d)  is being filed after the time period specified in §1.97(c), but before payment of the issue fee (37 C.F.R. §1.97(d)), and is accompanied by:

the statement specified in 37 C.F.R. §1.97(e); or

the fee set forth in 37 C.F.R. §1.17(p);

(e)  Pursuant to 37 C.F.R. §1.97(e)(1), each item of information contained in the attached Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

previous Information Disclosure Statements were filed on February 6, 2003, April 4, 2003, and May 12, 2006.

(f)  The art was encountered in the course of the prosecution of the corresponding foreign application(s) in

European Patent Application No. 03793209  
(name(s) of country(ies) and serial number(s))

3. **Identification of Person(s) Making This INFORMATION DISCLOSURE STATEMENT**

The person making this statement is

*(check each applicable item (a) and (b))*

(a)  the inventor(s) who signs below

SIGNATURE OF INVENTOR

Type name of inventor who is signing

(b)  the attorney who signs below on the basis of:


*(check each applicable item)*

the information supplied by the inventor(s)

which has been reviewed by the attorney

which has not been reviewed by the attorney

the information in the attorney's file



SIGNATURE OF ATTORNEY

Reg. No.: 44,529

Tel. No. (847) 770-6000

Donna E. Becker  
Type or Print Name of Attorney

650 Dundee Road, Suite #380  
P.O. Address

Northbrook, Illinois 60062

FORM PTO - 1449 (Modified)  
List of Patents and Publications  
For Applicant's Information  
Disclosure Statement  
(Use Several Sheets if Necessary)

ATTORNEY DOCKET NO: 6115-007  
APPLICANT: Ivan N. Rich  
FILING DATE: 1/29/02  
SERIAL NO: 10/059,521  
GROUP: 1641

### U.S. PATENT DOCUMENTS

Examiner's Initials	Ref. Desig.	Document Number	Date	Name	Class	Subclass
	AA					
	AB					
	AC					
	AD					
	AE					

### FOREIGN PATENT DOCUMENTS

Ref. Desig.	Document Number	Date	Country	Class	Subclass	Trans. Yes No
AF	98/21313	5/22/98	WIPO / PCT	C12N	5/08	
AG						
AH						
AI						
AJ						

### OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AK "Rapid differentiation of a rare subset of adult human lin(-)CD34(-) CD38 (-) cells stimulated by multiple growth factors in vitro", by Fujisaki, T., et al., Blood, Vol. 94, No.6, pp. 1926-1932 (September 15, 1999)

AL "Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors", by Gabbianelli, M., et al., Blood, Vol. 86, No. 5, pp. 1661-1670 (September 1, 1995)

AM "C-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia" by Ballmaier, M., et al., Blood, Vol. 97, No. 1, pp. 139 -146 (2001)

AN "The Effects of Oxygen Tension on Haemopoietic and Fibroblast Cell Proliferation In Vitro" by Bradley, T.R., et al., Journal of Cellular Physiology, Vol. 97, No. 3, pp. 517 – 522 (December 1978)

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.